September, 15 2014
Stevanato Group, leader in the production of insulin cartridges, glass containers for pharmaceutical use and technology for the development of glass tube forming machines, continues to grow.
Consolidated revenue at 30 June 2014 is 134,1 million Euro, +22,2% from the same period in 2013 (109,7 million Euro). Also in the second quarter 2014 significant increases have been registered in both divisions of the Group: Pharmaceutical Systems Division (87% of the revenue) and Engineering Systems Division (13% of the revenue).
“We are very satisfied of the performance had in this first half of the year. We registered an homogeneous growth in all the markets – states Franco Stevanato, CEO of the Group. – Our Pharmaceutical Systems Division specialized in the production of glass pharmaceutical vials, cartridges and syringes is growing faste ras the average of the competitors, keeping a high level of profitability. Our mission is to create systems and processes that guarantee the integrity of parenteral drugs, developing innovations that integrates product and process technology in order to develop systems that guarantee the integrity of this kind of products”.
These are the results of the strategy implemented in the last years, focusing on high added value products for the injectable primary packaging, and on the global geographical expansion. A local territorial coverage is in fact performed by Stevanato Group, in order to be always closed to the customer with new sales offices and production sites located where the business is growing.
“The recently inaugurated plant in Zhangjiagang, China, and the Mexican plant follow this strategy”, adds Marco Stevanato, Vice President of the Group. “The plant in Mexico is working at full capacity and we are already planning an expansion in order to meet the growing demand of high value products. Chinese plant will work at full capacity by the end of next year and we already planned a further expansion of the production area in line with the growth of the Far East market development. We are also planning to increase our presence by constructing new production sites in other geographical areas. We are conducting a scouting activity for the Brazilian market, already at the end stage”.
At the second quarter 2014 EBITDA is 32,1 million Euro (24,7 million Euro the year before) and EBIT is 20,5 million Euro (15 million Euro the year before).
Net Financial Position at 30 June 2014 is -63,2 million Euro, attributed to the huge investments made for the internationalization project, in line with the Industrial Plan.